NVS vs PFE
Novartis AG and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | NVS | PFE |
|---|---|---|
| Revenue | $54.5B | $62.6B |
| Net income | $14.0B | $7.8B |
| Gross margin | 78.8% | 74.3% |
| Net margin | 25.6% | 12.5% |
| Return on equity | 31.0% | 8.9% |
| Diluted EPS | $7.15 | $1.36 |
| Dividend / share | · | $1.72 |
| Payout ratio | · | · |
| Free cash flow | $17.6B | $9.1B |
| Equity | $46.1B | $86.5B |
| Net debt / equity | 0.37× | 0.73× |
| Current ratio | 1.12× | 1.16× |
| Revenue CAGR 5y | 2.3% | 8.5% |
| Profit CAGR 5y | 11.6% | −3.2% |
NVS and PFE book revenue within 15% of each other, and keeps more of each dollar of revenue as profit (25.6% against 12.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | NVS | PFE |
|---|---|---|
| FY2025 | $54.5B | $62.6B |
| FY2024 | $50.3B | $63.6B |
| FY2023 | $45.4B | $59.6B |
| FY2022 | $42.2B | $101.2B |
| FY2021 | $42.8B | $81.3B |
| FY2020 | $48.7B | $41.7B |
| FY2019 | $47.5B | $40.9B |
| FY2018 | $44.8B | $40.8B |
| FY2017 | $42.4B | $52.5B |
| FY2016 | $48.5B | $52.8B |
Bottom line
| Fiscal year | NVS | PFE |
|---|---|---|
| FY2025 | $14.0B | $7.8B |
| FY2024 | $11.9B | $8.0B |
| FY2023 | $14.8B | $2.1B |
| FY2022 | $7.0B | $31.4B |
| FY2021 | $24.0B | $22.0B |
| FY2020 | $8.1B | $9.2B |
| FY2019 | $11.7B | $16.0B |
| FY2018 | $12.6B | $11.2B |
| FY2017 | $7.7B | $21.3B |
| FY2016 | $6.7B | $7.2B |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$8,047,000,000 | PFE |
| FY2024 | −$13,310,000,000 | PFE |
| FY2023 | −$14,113,000,000 | PFE |
| FY2022 | −$58,969,000,000 | PFE |
| FY2021 | −$38,507,000,000 | PFE |
| FY2020 | +$7,008,000,000 | NVS |
| FY2019 | +$6,593,000,000 | NVS |
| FY2018 | +$4,008,000,000 | NVS |
| FY2017 | −$10,165,000,000 | PFE |
| FY2016 | −$4,306,000,000 | PFE |
The higher-revenue side has changed between NVS and PFE over this period. The gap has widened since the earliest year compared.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +13.1 pp | NVS |
| FY2024 | +11.1 pp | NVS |
| FY2023 | +29.1 pp | NVS |
| FY2022 | −14.6 pp | PFE |
| FY2021 | +29.0 pp | NVS |
| FY2020 | −5.5 pp | PFE |
| FY2019 | −14.5 pp | PFE |
| FY2018 | +0.7 pp | NVS |
| FY2017 | −22.5 pp | PFE |
| FY2016 | +0.1 pp | NVS |
The higher net margin has changed hands between NVS and PFE over this period.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PFE's net margin has been more volatile than NVS's over the 10 comparable fiscal years — 11.6 percentage points of standard deviation against 11.6.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between NVS and PFE over these 10 fiscal years — NVS led in 6 and PFE in 4.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PFE's return on equity has been more volatile than NVS's over the 10 comparable fiscal years — 11.1 percentage points of standard deviation against 9.6.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between NVS and PFE over these 10 fiscal years — NVS led in 4 and PFE in 6.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.